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Abstract 
Introduction: Cost of generic medications has risen more in the past few years than any other time in history. While medical insurance covers much of 
these costs, health care professionals can better provide medications that have the longest duration of action when compared to placebo-treated controls. 
This will save health care costs and improve prescribing accuracy.
Methods: Papers in PubMed were identified with keywords placebo. The study must be at least 2 years in length to evaluate the change in A1c over time. 
The primary endpoint was time to A1c neutrality (return of A1c to baseline at a maximum dose of single oral agent). A medication would be considered 
at neutrality if the 95% CI crossed baseline. Time to neutrality was averaged for each medication within the class and each summarized for class effect. 
Results: Effective therapy for the DPP-4 and sulfonylurea classes of medications are 3–4 years as compared to a 5-year time to A1c neutrality for metformin 
usage. In comparison, the projected time to A1c neutrality was approximately 6–8 years for rosiglitazone and pioglitazone. While only a few studies have 
been published in the SGLT-2 class of medication, the time to A1c neutrality was also 6–8 years with Canagliflozin and full dosage of Empagliflozin.
Conclusion: Metformin appears to have a 5-year duration of effect before the A1c returns to baseline. The sulfonylureas and DPP-4 inhibitors class of 
medications have one of the shortest durability which ranges between 3.3 to 4.4 years. In contrast, the SGLT-2 class of medication and the TZD class 
of medications has a projected time to A1c neutrality from 6–8 years. Diabetic duration of therapy as compared to placebo should be listed with those 
medications tested so the provider can choose wisely.
Introduction
ADA and AACE suggest that metformin be the first line medication 
for type 2 diabetes mellitus with many choices for the second line 
agent (ADA 2018, AACE 2016). Primary care health care professionals 
would benefit from understanding the potential durability of the 
diabetic medications to help improve compliance and reduce cost. 
Historically, sulfonylureas have been added second to metformin, 
fortunately, over the last 15 years, many combination agents have been 
developed that include metformin as one of the combo medications. 
So, the decision to choose the best second agent should be based on 
the evidence of safety and durability provided.
Limited studies have evaluated the long-term durability of a single 
diabetic agent on A1c control. The ADOPT trial used monotherapy 
with Metformin, Glyburide or Rosiglitazone and evaluated A1c 
changes over a 5-year period. Since the potential risk of rosiglitazone 
causing CV disease in 2008, the FDA has regulated that all diabetic 
medications have a CV trial to demonstrate safety. Prior to this 
regulation by the FDA, the ADOPT trial was a landmark study to 
evaluate the durability of single diabetic agents [1]. Since the 2008 
FDA requirement, all oral diabetic medications have been evaluated 
with a major endpoint being cardiovascular safety which requires large 
sample size and longer duration of therapy. Oral diabetic meds were 
evaluated in randomized, single agent, placebo-controlled clinical 
cardiovascular trials (with one exception being the TECOS trial) were 
used to also evaluate the durability of these oral medications based 
on baseline A1c nadir, return to baseline and compared to placebo 
treatment.
Methods
Based on the approach of the ADOPT [1] trial, where monotherapy 
was tried with three separate agents over an extended period of 
time (minimum 2 years), the study was designed to evaluate newer 
diabetic medications when given in placebo driven clinical trials for a 
minimum of 2 years. Trials with the several class of medications have 
recently been completed and the data summarized [2–9].
The ADOPT trial demonstrated what monotherapy with 
metformin, glyburide or rosiglitazone will reduce A1c levels over 
a 5-year period. Since DM-2 is considered a progressive disease 
with slow loss of the beta cell function, the waning effect of each 
medication was documented and projected time to A1c neutrality was 
documented over the 5-year study [1].
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The purpose of the trial was to clarify the duration of action of the 
more commonly used classes of medications. Traditionally the choice 
of medications has been limited and now there are over 20 combination 
oral medications for use in the treatment of type 2 diabetes. If the 
provider appreciates the duration of action of these medications then 
more appropriate choices can be made which should reduce the cost 
of medications and improve overall diabetic control.
Results 
 Three of the five FDA approved DPP-4 medications have had CV 
safety tested in a double-blind and placebo-controlled design. 
The first two agents’ saxagliptin (2) and alogliptin (8) were 
published on the same day (9/2/13) and they demonstrated a drop in 
A1c that was not significantly lower than baseline at the end of study. 
The Sitagliptin study showed a significant drop in A1c at 12 weeks but 
the difference from baseline was not significant after 34 weeks nor at 
the end of the 4-year study (Table 1 and Figure 1).  
Table 1.  Duration of A1c Effect over Time vs Placebo (Return to Baseline)
NAME  Dose (mg) Total Daily
Baseline A1c 
(%) Early (Nadir) Mid level End of Study
Time to A1c 
Neutrality
Alogliptin (EXAMINE) 30 8.0 -0.7/12w* -0.36/3yrs* 3.3yrs
Sitagliptin (Green) 100 7.2 -0.3/4w (NS) -0.2/34w (NS) -0.1%/4yrs 4.0 yrs
Saxagliptin (Scirica)  5 8.0 -0.5/104w -0%/4yrs 4.0 yrs                    
Gliptins: (3–4 yrs)
Glipizide  (Feinglos) 2.5 8.0 -0.5/14w 3.0 yrs
Glyburide  (ADOPT) 20 7.3 -0.90/12w 3.7yrs
Sulfas: (3–4 yrs)
Metformin (ADOPT) 2500 7.3 -0.60/52w 5.0yrs
Metformin: (5 yrs)
Rosiglitazone (ADOPT) 4–8 7.3 -0.67/104w 8.0yrs 
Pioglitazone (PROACTIVE) 45 7.8 -0.80/3yrs 6.0yrs
TZDs: (6–8 yrs)
Empagliflozin (EMPA) 10     8.1    -0.54/12w -0.42/94w -0.36/206w 5.0yrs
“ 25 8.1 -0.60/12w -0.47/94w -0.42/206w 8.0yrs 
Canaglifozin(CANVAS) 100/300 8.2 -0.70/26 w -0.40/156w -0.20/286w 7.0 yrs
SGLT-2: (5–7 yrs)
Figure 1. Projected durability of diabetic medications.
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The first of three DPP-4 clinical trials demonstrated that 
saxagliptin use for 2.1 years had no CV benefit and it reduced A1c 
from 8.0 to 7.7% which was 0.2% less than placebo [2]. Unfortunately, 
the SAVOR trial demonstrated that more saxagliptin-treated patients 
developed heart failure than placebo-treated patients (3.5% vs 2.8%; 
NNH = 143). This potential risk is listed with the FDA for health care 
professionals to evaluate and discuss with their patients [8]. Alogliptin 
treatment for 3 years dropped A1c from 8.0% to 7.67% which was 
0.36% less than the placebo at the end of the 3 years but there was no 
cardiovascular benefit observed [3]. Sitagliptin was given for 3 years 
and it had no CV benefit and it reduced the A1c from 7.3% to 7.1% 
which was 0.29% less than the placebo at the end of the 3 years [4]. 
In comparison, monotherapy was provided with glyburide over 5 
years and the results after 3 years demonstrated a significant drop in 
A1c from 7.3% to 7.1% (1). Low dose glipizide XL has 0.5% drop in A1c 
which nadirs, like glyburide at 12–14 weeks. Glipizide appears to have 
a shorter duration of action as it is projected to return to baseline at 
approximately 1 year. Likewise, metformin was given a monotherapy 
and the A1c dropped from 7.3% to 6.9% at 3 years. Rosiglitazone was 
also given and it dropped the A1c from 7.3% to 6.85% at 3 years [1]. 
The A1c returned to its baseline of 7.3% after 3.75 years of starting 
glyburide and after 5-years after starting metformin.
The TZD class of medications appears to provide for a longer 
duration of action. Interestingly, the A1c did not return to normal 
after 5 years of starting rosiglitazone as it remained significantly 
reduced at 7.1%. If you extend linear trend for A1c, it appears to take 
approximately 8 years for the A1c to return it to baseline of 7.3%. In 
the PROACTIVE trial, pioglitazone treatment for 3 years significantly 
reduced A1c from 7.8% to 7.0% at the end of 3 years [5]. The placebo-
treated patients drop their A1c by 0.3% at the end of study which 
showed no difference from baseline. 
Pioglitazone treatment in the PROACTIVE trial demonstrated 
a 0.8% drop in A1c at the end of the 3 years study with a predicted 
durability of 6.0 years [5]. In contrast, the Empagliflozin data 
demonstrated a 0.4% drop in A1c at the end of the 4-year study which 
projected to a 5-8 years durability of this therapy depend on the dose 
studied [6].
It would appear that the effective therapy for the DPP-4 class is 
approximately 3-4 years as compared to 5 years for the time for the 
A1c measurement to return the baseline level for metformin. The 5 
year duration of action for metformin was confirmed in the Diabetes 
Prevention Trial where FBG was 106 mg/dl at baseline and returned 
to 106 mg/dl after 5 years [17].  In the placebo arm the FBG increased 
from 106 to 112 mg/dl over the 5-year period.  In the 15 year follow up 
report the FBG increased to 117 mg/dl in the metformin arm, which 
is smaller then the projected change in A1c over time in Fig 1.   In 
contrast, the projected time to A1c baseline was approximately 6–8 
years for rosiglitazone and pioglitazone. While only two large studies 
have been published in the SGLT-2 class of medication, it appears that 
the time to A1c neutrality was seen Canagliflozin was 7 years [7] and 
with Empagliflozin an estimated 5 years with a low dose and 8 years 
with high dose [6].
Discussion
The natural history of type 2 diabetes mellitus appears to be due 
to persistent loss of the beta-cell function over time. While there 
can be an increase in insulin resistance that can occur with aging or 
weight gain, the majority of the waning effect of diabetic medications 
are likely due to the natural loss of insulin secretion. Why this rate is 
different with different medication is unknown.
We know that fasting insulin levels are increased with glyburide 
treatment and remain neutral with both metformin and DPP-4 
inhibitors. The mechanism of the DPP-4 inhibitors is to increase 
incretin levels (GLP-1 and GIP), which inhibits glucagon release, 
which in turn increases insulin secretion, decreases gastric emptying 
and decreases blood glucose levels. While metformin has a neutral 
effect, the administration of TZD medication and that of the SGLT-2 
medication are associated with a significant reduction in the fasting 
insulin levels [10]. The reduction in the insulin levels is unlikely to 
play a major role in the durability because of the failure of Origins trial 
to delay the onset of DM-2, where basal insulin was administered for 
5 years [11]. So, TZD and SGLT-2 class appear to have a direct drug 
effect on the beta cell and/or other pathways of insulin resistance. We 
know that liver fat, beta cell fat and selective muscle fat is reduced 
with TZD treatment [10]. Likewise, weight loss seen with the SGLT-2 
inhibitors can be associated with similar changes in these tissues that 
could both reduce insulin resistance and increase insulin secretion.
Diabetes appears to be a progressive disease process with slow 
but consistent loss of control over 6 to 12 months of therapy in many 
patients. It is well known that the use of TZD reduces carotid intima 
thickness as compared to glimepiride [10], it reduces liver fat content 
by 54% [12] and improves insulin resistance and beta cell function 
[10]. Metformin prevents the production of glucose in both the liver 
and kidney which may reduce the insulin requirements associated 
with hormonal or metabolic factors that would otherwise rise insulin 
secretion. 
This raises two interesting points: durability of each class of 
medications and potential mechanism of action of these medications. 
The best durability appears to be in the TZD and SGLT-2 classes which 
appears... to have a projected effect on A1c of greater than 6–8 years 
while metformin has limited benefit of approximately 5-years before 
the A1c returns to baseline [1]. The shortest durability is seen in the 
DPP-4 medications, which have 3–4 years projected time to A1c 
neutrality. Therefore, the time for A1c neutrality appears to be the 
shortest for the DPP-4 and sulfa classes of medications. 
What to do about the waning effect of several classes of mediations: 
The current answer is unknown, but if the effective treatment benefit 
of a DPP-4 medication is approximately 3–4 years and metformin 
has 5 years, it seems clear that metformin has both durability and 
cost savings. The combinations agents with both metformin and 
DPP-4s may misleading health care professionals to its durability 
since metformin is likely doing the majority of the treatment effect. 
Interestingly, the use of rosiglitazone, the medication that caused the 
introduction of the FDA for Cardiovascular Outcome trials to confirm 
CV neutrality has been shown to have one of the two longest duration 
of benefit for A1c reduction over time.
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Caution about the use of both Rosiglitazone and Pioglitazone 
exists in the medical literature. Rosiglitazone was put on restricted 
usage requiring REMS after Dr. Steve Nisson published his analysis of 
the increase CV risk that appears to be associated with rosiglitazone 
[15]. This REMS requirement for rosiglitazone was withdrawn by 
the FDA after publication of the RECORD trial where there was no 
CV risk associated with rosiglitazone [16]. This class of medications 
is contraindicated in CHF stage 3 or 4. They are known to cause 
intravascular fluid retention and also to cause lower extremity swelling 
which is likely due to pre-adipocyte differentiation into adipocytes. 
This class of medications lowers fasting insulin levels and also lower 
IGF-1 concentrations which likely explains the loss of bone mass over 
time. The TZD class of medications should be avoided in patients with 
significant osteoporosis. 
In comparison to the downsides of using the TZD class of 
medication, there is growing evidence suggests that pioglitazone 
treatment has shown a 51% resolution of NASH and reduces fibrosis 
[13]. In addition, pioglitazone has been shown to help reduce 
recurrent CVA in diabetics [5] and pre-diabetics [14]. Similarly, the 
SGLT-2 medication Empagliflozin has been approved by the FDA 
to reduce CV risk and it has a projected long-term reduction in A1c 
levels. Based on the duration of action, potential CV risk reduction, 
this medication would be an excellent choice for diabetic patients at 
risk for CV events. Likewise, pioglitazone may be a wise choice for 
pre-diabetic or diabetic patients who have had a recent CVA event or 
have F3-F4 fibrosis or proven NASH. Additional CV outcome trials 
with newer diabetic medications will also provide the provider with 
duration of effect estimate which may help improve compliance and 
reduce health care costs.
In conclusion, the primary care provider should consider the 
durability of treatment in their treatment decision after starting 
metformin. The A1c durability of each agent should be included in 
treatment guidelines for ACP, ADA, AACE and European Diabetic 
Guidelines. In the time of abundant oral diabetic medications, effort 
should be used to educate health care professionals on the duration of 
action as well as potential non-diabetic risk and benefits of diabetic 
agents. More studies on the comprehensive effective long-term, 
placebo-controlled monotherapy treatment trials will allow the health 
care professionals can choose wisely for their patients. 
In summary, the duration of A1c effect was 5 years for metformin 
and it appears to be a better choice over a sulfa and DPP-4 class of 
medications. A longer duration of action was seen with the SGLT-2 
and TZD class of medications. These both have a long duration of 
action (6–8 yrs), and with their low cost may be considered in patients 
who would benefit from their use. 
With the recent adoption by the ACP (American College of 
Physicians) that target A1c of < 8% is “at goal” for diabetic patients, 
then metformin should provide 5 years of acceptable diabetic control 
if stating at an A1c of 8%. Our data would suggest that mono-therapy 
with a SGLT-2 inhibitor or PPAR-gamma agonist (TZD) would keep 
someone at goal for approximately 7-8 years if the starting A1c was 
8%. Using this stepwise triple therapy approach, it may be possible 
for a diabetic patient to maintain their A1c at goal for approximately 
20 years.
Acknowledgement: The NIH Clinical Investigator Award 
KO8DK02083 and MO1-RR-00425 supported this grant
References
1. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, et al. (2007) Glycemic 
durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 
355: 2427–2443. [crossref]
2. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, et al. (2013) Saxagliptin 
and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 
369: 1317–1326. [crossref] 
3. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, et al. (2013) 
Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J 
Med 369: 1327–1335. [crossref] 
4. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, et al. (2015) Effect of 
Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 373: 
232–242. [crossref]
5. Dormandy JA1, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, et al. 
(2005) PROactive Investigators. Secondary prevention of macrovascular events in 
patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone 
Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet 366: 
1279–1289. [crossref]
6. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, et al. (2015) Empagliflozin, 
cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373: 
2117–2128. [crossref]
7. Mahaffey KW, Neal B, Perkovic V, de Zeeuw D, Fulcher G, et al. (2017) 
Canagliflozin for primary and secondary prevention of cardiovascular events: 
Results from the CANVAS program. Circulation 137: 323–334.
8. Kongwatcharapong J, Dilokthornsakul P, Nathisuwan S, Phrommintikul A, 
Chaiyakunapruk N (2016) Effect of dipeptidyl peptidase-4 inhibitors on heart 
failure: A meta-analysis of randomized clinical trials. Int J Cardiol 211: 88–95. 
[crossref] 
9. Feinglos M, Dailey G, Cefalu W, Osei K, Tayek J, et al. (2005) Effect of glycemic 
control of the addition of 2.5 mg glipizide GITS to metformin in patients with type 
2 diabetes. DM Res Clin Prac 68: 167–182.
10. Langerfeld MR, Forst T, Hohberg C, et al. (2005) Pioglitazone decreases carotid 
intima-media thickness independently of glycemic control in patients with type 
2 diabetes mellitus: Results from a controlled randomized study. Circulation 17: 
2525–2531. [crossref]
11. Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, et al. (ORIGINS Investigators) 
(2012) Basal insulin and cardiovascular and other outcomes in dysglycemia. N Eng 
J Med 367: 319–328. [crossref]
12. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J (2006) A placebo-
controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Eng 
J Med 355: 2297–307. [crossref]
13. Cusi K, Orsak B, Bril F, Lomonaco R, Hecht J, et al. (2016) Long-term pioglitazone 
treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 
diabetes mellitus: A randomized trial. Ann Intern Med 305–315. [crossref]
14. Kernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, et al.  (2016) 
Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med 374: 
1321–1331. [crossref] 
15. Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial 
infarction and death from cardiovascular causes. N Engl J Med 356: 2457–71. 
[crossref] 
16. Mahaffery KW, Kafley G, Dickerson S, Burns S, Tourt-Uhlig S, et al. (2013) 
Results of reevaluation of cardiovascular outcomes in the RECORD trial. Am Heart 
J 166: 240–249. [crossref]
17. Nathan DM et el (Diabetes Prevention Program Research Group), Long term effects 
of lifestyle intervention or metformin on diabetes development and microvascular 
complications over 15-year follow-up: the Diabetes Prevention Program Outcome 
Study. (2015) Lancet Diabetes Endocrinol 3: 866–875.
Citation: 
Lavanya Cherukuri, Michael S. Smith, John A. Tayek (2018) The durability of 
oral diabetic medications: Time to A1c baseline and a review of common oral 
medications used by the primary care provider. Endocrinol Diabetes Metab J 
Volume 2(3): 1–4
